TSHA logo

Taysha Gene Therapies (TSHA) EBITDA

annual EBITDA:

-$87.95M+$17.25M(+16.39%)
December 31, 2024

Summary

  • As of today (June 22, 2025), TSHA annual EBITDA is -$87.95 million, with the most recent change of +$17.25 million (+16.39%) on December 31, 2024.
  • During the last 3 years, TSHA annual EBITDA has risen by +$84.65 million (+49.04%).
  • TSHA annual EBITDA is now -46.65% below its all-time high of -$59.97 million, reached on December 31, 2020.

Performance

1-year change

+16.39%

3-year change

+49.04%

5-year change

-

15-year change

-

TSHA EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

20.52%
TSHA annual EBITDA is higher than 20.52% of companies in Healthcare sector

Range

All-time high

-$59.97M

3-year low

-$172.60M

Earnings dates

Last annual earnings report date

Dec 31, 2024
TSHA previous annual earnings announcement was published on Dec 31, 2024

Next annual earnings report date

N/A
TSHA next annual earnings announcement has not yet been scheduled

OtherTSHAincome statement metrics

Annual revenue

$8.33M
TSHA annual revenue is $8.33 million

annual net income

-$89.30M
TSHA annual net profit is -$89.30 million

annual EBIT

-$89.20M
TSHA annual earnings before interest & taxes is -$89.20 million

Annual EPS

-$0.36
TSHA annual earnings per share is -$0.36

quarterly EBITDA:

-$21.23M-$2.77M(-15.00%)
March 31, 2025

Summary

  • As of today (June 22, 2025), TSHA quarterly EBITDA is -$21.23 million, with the most recent change of -$2.77 million (-15.00%) on March 31, 2025.
  • Over the past year, TSHA quarterly EBITDA has increased by +$2.48 million (+10.46%).
  • TSHA quarterly EBITDA is now -143.48% below its all-time high of $48.82 million, reached on December 31, 2023.

Performance

3-month change

-15%

1-year change

+10.46%

3-year change

+57.02%

5-year change

-292.8%

TSHA quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

21.97%
TSHA quarterly EBITDA is higher than 21.97% of companies in Healthcare sector

Range

All-time high

$48.82M
TSHA quarterly EBITDA is currently -143.48% below its historical high of $48.82 million

3-year low

-$115.28M

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
TSHA previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Aug 12, 2025
TSHA next earnings announcement is scheduled for Aug 12, 2025

OtherTSHAincome statement metrics

Quarterly revenue

$2.30M
TSHA quarterly revenue is $2.30 million

quarterly net income

-$21.53M
TSHA quarterly net profit is -$21.53 million

quarterly EBIT

-$21.51M
TSHA quarterly earnings before interest & taxes is -$21.51 million

Quarterly EPS

-$0.08
TSHA quarterly earnings per share is -$0.08

TTM EBITDA:

-$85.47M+$2.48M(+2.82%)
March 31, 2025

Summary

  • As of today (June 22, 2025), TSHA TTM EBITDA is -$85.47 million, with the most recent change of +$2.48 million (+2.82%) on March 31, 2025.
  • Over the past year, TSHA TTM EBITDA has increased by +$27.52 million (+24.35%).
  • TSHA TTM EBITDA is now -7565.56% below its all-time high of -$1.11 million, reached on December 1, 2019.

Performance

3-month change

+2.82%

1-year change

+24.35%

3-year change

+55.01%

5-year change

-1211.11%

TSHA TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

21.29%
TSHA TTM EBITDA is higher than 21.29% of companies in Healthcare sector

Range

All-time high

-$1.11M

3-year low

-$207.43M

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
TSHA previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Aug 12, 2025
TSHA next earnings announcement is scheduled for Aug 12, 2025

OtherTSHAincome statement metrics

TTM revenue

$7.22M
TSHA TTM revenue is $7.22 million

TTM net income

-$86.77M
TSHA TTM net profit is -$86.77 million

TTM EBIT

-$86.67M
TSHA TTM earnings before interest & taxes is -$86.67 million

TTM EPS

-$0.34
TSHA TTM earnings per share is -$0.34

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

annual EBITDA

-$87.95M
TSHA annual EBITDA is -$87.95 million

annual net income

-$89.30M
TSHA annual net profit is -$89.30 million

annual interest expense

$102.00K
TSHA annual interest expense is $102.00 thousand

annual income tax

-
TSHA annual income tax value is unknown

annual D&A

$1.25M
TSHA annual depreciation & amortization is $1.25 million

TSHA EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+16.4%+10.5%+24.4%
3 y3 years+49.0%+57.0%+55.0%
5 y5 years--292.8%-1211.1%

TSHA EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+49.0%-143.5%+81.6%-313.5%+58.8%
5 y5-year-46.6%+49.0%-143.5%+81.6%-1211.1%+58.8%
alltimeall time-46.6%+49.0%-143.5%+81.6%-7565.6%+58.8%

TSHA EBITDA History

DateAnnualQuarterlyTTM
Mar 2025
-
-$21.23M(+15.0%)
-$85.47M(-2.8%)
Dec 2024
-$87.95M(-16.4%)
-$18.46M(-26.8%)
-$87.95M(+325.5%)
Sep 2024
-
-$25.21M(+22.5%)
-$20.67M(-81.3%)
Jun 2024
-
-$20.58M(-13.2%)
-$110.75M(-2.0%)
Mar 2024
-
-$23.71M(-148.6%)
-$112.99M(+7.4%)
Dec 2023
-$105.20M(-34.7%)
$48.82M(-142.3%)
-$105.20M(-49.3%)
Sep 2023
-
-$115.28M(+405.3%)
-$207.43M(+76.8%)
Jun 2023
-
-$22.82M(+43.3%)
-$117.31M(-8.0%)
Mar 2023
-
-$15.92M(-70.2%)
-$127.58M(-20.8%)
Dec 2022
-$161.04M
-$53.41M(+112.2%)
-$161.04M(+2.5%)
Sep 2022
-
-$25.17M(-23.9%)
-$157.12M(-13.9%)
DateAnnualQuarterlyTTM
Jun 2022
-
-$33.08M(-33.0%)
-$182.43M(-4.0%)
Mar 2022
-
-$49.38M(-0.2%)
-$190.00M(+10.1%)
Dec 2021
-$172.60M(+187.8%)
-$49.49M(-2.0%)
-$172.60M(+22.0%)
Sep 2021
-
-$50.48M(+24.2%)
-$141.43M(+33.4%)
Jun 2021
-
-$40.65M(+27.1%)
-$105.99M(+22.4%)
Mar 2021
-
-$31.99M(+74.7%)
-$86.56M(+44.3%)
Dec 2020
-$59.97M
-
-
Dec 2020
-
-$18.31M(+21.8%)
-$59.97M(+40.2%)
Sep 2020
-
-$15.04M(-29.1%)
-$42.78M(+54.2%)
Jun 2020
-
-$21.22M(+292.7%)
-$27.74M(+325.5%)
Mar 2020
-
-$5.40M(+384.7%)
-$6.52M(+484.7%)
Dec 2019
-
-$1.11M
-$1.11M

FAQ

  • What is Taysha Gene Therapies annual EBITDA?
  • What is the all time high annual EBITDA for Taysha Gene Therapies?
  • What is Taysha Gene Therapies annual EBITDA year-on-year change?
  • What is Taysha Gene Therapies quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Taysha Gene Therapies?
  • What is Taysha Gene Therapies quarterly EBITDA year-on-year change?
  • What is Taysha Gene Therapies TTM EBITDA?
  • What is the all time high TTM EBITDA for Taysha Gene Therapies?
  • What is Taysha Gene Therapies TTM EBITDA year-on-year change?

What is Taysha Gene Therapies annual EBITDA?

The current annual EBITDA of TSHA is -$87.95M

What is the all time high annual EBITDA for Taysha Gene Therapies?

Taysha Gene Therapies all-time high annual EBITDA is -$59.97M

What is Taysha Gene Therapies annual EBITDA year-on-year change?

Over the past year, TSHA annual EBITDA has changed by +$17.25M (+16.39%)

What is Taysha Gene Therapies quarterly EBITDA?

The current quarterly EBITDA of TSHA is -$21.23M

What is the all time high quarterly EBITDA for Taysha Gene Therapies?

Taysha Gene Therapies all-time high quarterly EBITDA is $48.82M

What is Taysha Gene Therapies quarterly EBITDA year-on-year change?

Over the past year, TSHA quarterly EBITDA has changed by +$2.48M (+10.46%)

What is Taysha Gene Therapies TTM EBITDA?

The current TTM EBITDA of TSHA is -$85.47M

What is the all time high TTM EBITDA for Taysha Gene Therapies?

Taysha Gene Therapies all-time high TTM EBITDA is -$1.11M

What is Taysha Gene Therapies TTM EBITDA year-on-year change?

Over the past year, TSHA TTM EBITDA has changed by +$27.52M (+24.35%)
On this page